Stelios Loukides
Overview
Explore the profile of Stelios Loukides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
1743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papaioannou A, Loukides S, Vassilakopoulos T, Tzanakis N, Kostikas K, Hillas G
Int J Chron Obstruct Pulmon Dis
. 2025 Mar;
20:457-471.
PMID: 40041472
Background: In recent years, COPD treatment has become more personalized considering specific patient's characteristics. Aim And Methods: We have performed a DELPHI consensus project to assess the level of consensus...
2.
Porpodis K, Zias N, Kostikas K, Tzouvelekis A, Makris M, Konstantinou G, et al.
Clin Transl Allergy
. 2025 Jan;
15(2):e70035.
PMID: 39887925
Background: Data on type 2 (T2)-low severe asthma (SA) frequency is scarce, resulting in an undefined unmet therapeutic need in this patient population. Our objective was to assess the frequency...
3.
Voulgareli I, Antonogiannaki E, Bartziokas K, Zaneli S, Bakakos P, Loukides S, et al.
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860403
Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) have a substantial effect on overall disease management, health system costs, and patient outcomes. However, exacerbations are often underdiagnosed or recognized with great...
4.
Antonogiannaki E, Grigoropoulos I, Manali E, Thomas K, Kallieri M, Alexopoulou P, et al.
J Clin Med
. 2025 Jan;
14(2.
PMID: 39860353
: Long-term lung sequelae in severe COVID-19 survivors, as well as their treatment, are poorly described in the current literature. : To investigate lung fibrotic sequelae in survivors of severe/critical...
5.
Papaioannou A, Kallieri M, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, et al.
Allergy Asthma Proc
. 2024 Dec;
46(1):45-51.
PMID: 39741370
Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. In this post...
6.
Bartziokas K, Papaioannou A, Rovina N, Papaiakovou G, Loukides S, Steiropoulos P
Pulm Ther
. 2024 Dec;
11(1):7-24.
PMID: 39661227
The latest advances in asthma treatment have highlighted the significance of eosinophilia and the possible role of some pro-eosinophilic mediators, like interleukins (IL) IL-5, IL-4/IL-13, and IL-33 in the disease's...
7.
Verykokou G, Papaioannou A, Apollonatou V, Kavatha D, Boumpas D, Papiris S, et al.
Exp Ther Med
. 2024 Nov;
29(1):8.
PMID: 39563884
During the coronavirus disease-19 (COVID-19) pandemic, there was an unprecedented requirement for hospital bed availability. The present study aimed to examine the characteristics and outcomes of patients hospitalized in a...
8.
Domvri K, Tsiouprou I, Bakakos P, Steiropoulos P, Katsoulis K, Kostikas K, et al.
J Allergy Clin Immunol
. 2024 Nov;
155(2):425-435.
PMID: 39521278
Background: Clinical trials and real-world experience have provided evidence for the clinical benefits of mepolizumab, an anti-IL-5 biologic, in severe asthma. However, limited data exist regarding the impact of mepolizumab...
9.
Schoini P, Apollonatou V, Kallieri M, Blizou M, Sfika M, Koufopoulos N, et al.
J Clin Med
. 2024 Oct;
13(19).
PMID: 39407896
: Sensitization to specific IgE enterotoxins (SEs) is associated with an increased risk for severe asthma development. Limited data exist regarding the association of seropositivity for specific IgE SEs and...
10.
Sfika M, Kasdagli M, Naska A, Blizou M, Schoini P, Voulgareli I, et al.
J Asthma
. 2024 Oct;
62(3):541-547.
PMID: 39401148
Objectives: Current variations in asthma prevalence and clinical characteristics suggest that lifestyle choices including dietary habits, may affect the pathogenesis and/or clinical expression of the disease. The purpose of this...